Ji Cho
Adult Health · Philadelphia, PANPI 1912200635
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,106 of the $9,167 with a category attached, or 77.5%. 20 manufacturers reported payments, led by AbbVie at 37.2% of the total. Among adult health clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 387 payments — averaging $23.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Lundbeck LLC$1K
- Biodelivery Sciences International, Inc.$750
- Teva Pharmaceuticals USA, Inc.$637
- Pfizer$621
- Impel Pharmaceuticals Inc.$537
- plus $2K from 14 others
What the payments were for
- Consulting fees$1,31114%
- Speaking & faculty fees$7508%
- Food & beverage$7,10678%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 182 | $3,406 |
| Lundbeck LLC | 11 | $1,108 |
| Biodelivery Sciences International, Inc. | 1 | $750 |
| Teva Pharmaceuticals USA, Inc. | 40 | $637 |
| Pfizer | 32 | $621 |
| Impel Pharmaceuticals Inc. | 22 | $537 |
| Biohaven Pharmaceuticals, Inc. | 12 | $477 |
| Lilly USA, LLC | 26 | $476 |
| Biohaven Pharmaceutical Holding Company Ltd. | 20 | $370 |
| Upsher-smith Laboratories LLC | 14 | $268 |
| Amgen | 13 | $240 |
| Axsome Therapeutics, Inc. | 3 | $66 |
| Ipsen Biopharmaceuticals, Inc | 3 | $49 |
| Impel Pharmaceuticals LLC | 2 | $39 |
| Tonix Medicines, Inc. | 1 | $29 |
| Scilex Pharmaceuticals Inc. | 1 | $23 |
| Biogen | 1 | $22 |
| Eisai Inc. | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYEPTI$911
- ELYXYB - CELECOXIB$750
- Trudhesa$132
- UBRELVY$125
- QULIPTA$125
- NURTEC ODT$114
How this compares
$9,167 in reported general payments places this provider in the 95th percentile of 899 adult health providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 60 | $99,522 |
| Emgality PenGalcanezumab-Gnlm | 92 | $63,695 |
| UbrelvyUbrogepant | 48 | $59,012 |
| Aimovig AutoinjectorErenumab-Aooe | 68 | $51,615 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 54 | $39,163 |
| QuliptaAtogepant | 35 | $37,741 |
| Emgality SyringeGalcanezumab-Gnlm | 13 | $22,934 |
| Ajovy SyringeFremanezumab-Vfrm | 18 | $17,171 |
| Topiramate ErTopiramate | 16 | $12,473 |
| Dihydroergotamine Mesylate | 18 | $10,473 |
| Mexiletine Hcl | 22 | $2,641 |
| Candesartan Cilexetil | 23 | $1,943 |
| Topiramate | 108 | $1,431 |
| Eletriptan HbrEletriptan Hydrobromide | 18 | $1,261 |
| Gabapentin | 57 | $1,191 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $621 | $99,52260 claims |
| AbbVieUbrelvy, Qulipta | $3,406 | $96,75383 claims |
| Upsher-smith Laboratories LLCTopiramate | $268 | $1,431108 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 899 adult health providers in Pennsylvania.
Other adult health in Philadelphia
- Beth SandyPhiladelphia$924K
- Diane NewmanPhiladelphia$343K
- Abigail SmithPhiladelphia$302K
- Catherine HoldsworthPhiladelphia$64K
- Kevin CarneyPhiladelphia$53K
- Christine ChmielewskiPhiladelphia$52K
- Barbara RogersPhiladelphia$51K
- Joyce RossPhiladelphia$39K
- Veronica RichardsonPhiladelphia$33K
- Tetyana FurmanetsPhiladelphia$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.